Daiichi Sankyo Australia: The Next Chapter in Oncology Innovation
In Australia, Daiichi Sankyo is more than a pharmaceutical company; we are a dedicated partner in the fight against cancer.
Despite significant advancements in science, cancer continues to claim too many lives. The need for innovative treatments is urgent.
Our pipeline, which includes medicines utilising our proprietary DXd (deruxtecan) ADC (antibody drug conjugate) technology as well as other novel entities, targets a wide range of difficult-to-treat cancers, including breast, lung, gastric, ovarian, and endometrial.
With a growing number of clinical trials across the country, we aim to ensure Australian patients benefit from the latest advancements in cancer care.
We are proud to partner with researchers, clinicians, patients, advocates, and government to deliver these solutions and advance the fight against cancer.
Built on Values, Awarded for Excellence
At Daiichi Sankyo Australia, we are committed to fostering a collaborative and inclusive culture that fully aligns with the global Daiichi Sankyo Core Values and Core Behaviours.
Based on employee feedback, we know our people feel valued, empowered, and supported to succeed.
We take pride in our intentional and ongoing efforts, which have been recognised nationally in prestigious award competitions alongside organisations from diverse industries.
Below are some of the key certifications and awards that highlight our achievements and dedication to our people.
Certified Great Place To Workin April 2025
Daiichi Sankyo Australia is proud to be officially certified as a Great Place to Work®, a recognition
that reflects our commitment to creating an inclusive, supportive, and engaging workplace. This certification is based on direct feedback from our employees, and we are thrilled to have achieved an impressive 96% employee satisfaction rate.
Certified Family Inclusive Workplace™in September 2023 and September 2025
Daiichi Sankyo Australia was first certified as a Family Inclusive Workplace™ in September 2023, just 6 months after commencing operations, and proudly re-certified in September 2025. This achievement reaffirms our commitment to supporting employees in balancing work and family responsibilities.
We have established policies and practices that foster flexibility, inclusivity, and wellbeing for all team members.
Want to learn more about our approach?
Read our case-study on the Family Friendly Workplaces website to see how we’re making a difference.
Honoured at the Australian HR Awards 2025
At the renowned Australian HR Awards 2025, Daiichi Sankyo Australia was named Winner in the Employer of Choice (1–99 Employees) category, recognising its commitment to creating an exceptional workplace where employees feel valued and supported.
Daiichi Sankyo Australia was also honoured as an Excellence Awardee in the Best Workplace Flexibility Program category, highlighting its strong focus on flexible work arrangements that help employees thrive both professionally and personally.
These prestigious awards demonstrate Daiichi Sankyo Australia’s ongoing efforts to create an environment where innovation, collaboration, and employee wellbeing are at the forefront.
Daiichi Sankyo Group Employee Code of Conduct
At Daiichi Sankyo, integrity, innovation, and accountability are at the heart of everything we do. Our Employee Code of Conduct outlines the principles and expectations that guide our actions worldwide. It embodies our commitment to ethical behaviour, strict compliance with laws and regulations, and fostering a culture of trust and transparency.
Thorough compliance is essential for the continuation of corporate activities in society.
Therefore, as a global group of pharmaceutical companies, we consider compliance practices as continuing to earn the trust of our diverse stakeholders, and we conduct activities with high ethical standards that take into account not only internal standards, but also social consciousness, philosophy, and social contribution, while adhering to the applicable laws and regulations of the markets in which we operate.
The Daiichi Sankyo group of companies defines “Integrity” as one of our Core Values. We have therefore positioned compliance as the standard we use in making decisions and judging values. In conducting our global business operations, we conduct compliance management with a strong focus on ensuring the high standards of ethics, which is essential for a healthcare company.
To help employees deepen their understanding of this concept and embody it in practice, we have established the Daiichi Sankyo Group Corporate Conduct Charter and the Daiichi Sankyo Group Employee Code of Conduct as the Group’s common codes of conduct.
Every Daiichi Sankyo employee plays a vital role in upholding these standards, helping us continue to make a meaningful impact for patients, communities, and one another.
To learn more, view the Global Ethics & Compliance page